Tag - SRNE

Dawson James Securities launched coverage of Sorrento Therapeutics (NASDAQ:SRNE) with a “buy” rating and $24 price target. The stock closed at $5.07 on May 22. Analyst Jason Kolbert writes that Sorrento’s STI-1499...